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IL-33/ST2 signalling and crosstalk 
with FcεRI and TLR4 is targeted by 
the parasitic worm product, ES-62
Dimity H. Ball1, Lamyaa Al-Riyami2, William Harnett2 & Margaret M. Harnett  1
ES-62 is a secreted parasitic worm-derived immunomodulator that exhibits therapeutic potential in 
allergy by downregulating aberrant MyD88 signalling to normalise the inflammatory phenotype and 
mast cell responses. IL-33 plays an important role in driving mast cell responses and promoting type-2 
allergic inflammation, particularly with respect to asthma, via MyD88-integrated crosstalk amongst the 
IL-33 receptor (ST2), TLR4 and FcεRI. We have now investigated whether ES-62 targets this pathogenic 
network by subverting ST2-signalling, specifically by characterising how the functional outcomes of 
crosstalk amongst ST2, TLR4 and FcεRI are modulated by the worm product in wild type and ST2-
deficient mast cells. This analysis showed that whilst ES-62 inhibits IL-33/ST2 signalling, the precise 
functional modulation observed varies with receptor usage and/or mast cell phenotype. Thus, whilst ES-
62’s harnessing of the capacity of ST2 to sequester MyD88 appears sufficient to mediate its inhibitory 
effects in peritoneal-derived serosal mast cells, downregulation of MyD88 expression appears to be 
required to dampen the higher levels of cytokine production typically released by bone marrow-derived 
mucosal mast cells.
Reflecting the broad expression of its receptor (IL-33R, comprising ST2 [also known as IL1RL1, IL-1R4] and 
IL-1RAcP [IL-1R3]) on immune system cells (mast cells and Th2 cells, activated Th1, Treg, ILC2, CD8+ T cells 
and NK cells), IL-33 has been proposed to play key roles in innate and adaptive immunity and also in the res-
olution of inflammation and promotion of tissue repair1. In addition, IL-33 has increasingly been implicated 
in the pathogenesis of a wide range of inflammatory diseases, but particularly in asthma where GWAS studies 
have demonstrated clear association of the IL-33 and IL-1RL1 genes with human asthma and ST2-deficiency in 
mice results in suppression of acute eosinophilic inflammation and airway hyper-responsiveness (AHR)1,2. Mast 
cells are a major player in the induction and promulgation of such allergic inflammation as allergen-induced 
crosslinking of FcεRI results in the release of a wide range of pro-inflammatory mediators (including histamine, 
cytokines, proteases and prostaglandins), which regulate a variety of disease parameters including recruitment of 
inflammatory cells, smooth muscle contraction and vascular permeability. Moreover, these FcεRI-mediated mast 
cell responses can be modulated by various stimuli including LPS (via TLR4) and IL-33, both of which have been 
shown to amplify mast cell responsiveness and exacerbate AHR3–8 and perhaps pertinently, are present during 
bacterial infection, a clinical situation that can aggravate established asthma9.
By contrast, ES-62, a phosphorylcholine-containing glycoprotein immunomodulator secreted by the parasitic 
worm, Acanthocheilonema viteae, protects against airway inflammation and lung pathology in both acute and 
chronic models of asthma10–12 by subverting TLR4 signalling and inducing mast cell hyporesponsiveness10,12–14. 
In particular, ES-62 appears to act by targeting aberrant signalling via MyD88 to reset the homeostatic regula-
tory: effector cell balance of the immune response and thereby normalise dysregulated inflammatory pheno-
types in allergic and autoimmune disease15,16. MyD88 has recently been suggested to provide a key regulatory 
node in the convergent crosstalk amongst IL-33/ST2, LPS/TLR4 and FcεRI that leads to the generation of type-2 
responses1,5,17–22. This idea is consistent with the ability of ST2 to block MyD88’s association with TLR423 and in 
macrophages, inhibit LPS/TLR4-mediated NF-κB activation and consequent release of IL-6 and IL-12, cytokines 
that promote Th1/Th17-responses, by sequestering MyD88 via its TIR domain. As LPS signalling upregulates 
ST2 expression in monocytes/macrophages, these data led to the proposal that ST2 may act to limit LPS/TLR4 
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proinflammatory responses, a hypothesis supported by the failure of ST2-deficient mice to develop endotoxin 
tolerance1,24.
Thus, to explore the possibility that ES-62 may act to suppress this pathogenic network in allergic conditions, 
we have now investigated whether it can subvert IL-33/ST2/MyD88 signalling to modulate the proinflamma-
tory responses resulting from crosstalk between ST2, FcεRI and TLR4. Specifically, by exploiting ST2-deficient 
cells, we first characterised how IL-33/ST2 signalling differentially shapes FcεRI- and TLR4-driven responses 
in distinct subsets of mast cells, before moving on to determine the ST2-dependence of ES-62-driven modula-
tion of this pathogenic network. This approach showed that ES-62 could suppress IL-33/ST2-induced cytokine 
(IL-6 and IL-13) responses in both serosal peritoneal-derived mast cells (PDMCs) and bone marrow-derived 
mucosal mast cells (BMMCs). However, whilst the ability of ES-62 to mediate its inhibitory effects on LPS/TLR4 
or IL-33/ST2 + LPS/TLR4 responses was found to be ST2-dependent in PDMCs, this was not the case in BMMCs. 
Collectively, therefore, our data support the utility of exploiting ES-62 to dissect the mechanisms regulating 
inflammatory networks and the potential of MyD88 as a target for therapeutic intervention in the differential 
(receptor-, inflammation site- and subtype-specific-) pathogenic mast cell responses associated with allergy.
Results
IL-33 signalling and pro-inflammatory responses in PDMCs and BMMCs. IL-33 stimulates pro-
duction of the cytokines, IL-6 and IL-13 and the chemokine, CCL2 by PDMCs and BMMCs: the release of all 
three pro-inflammatory mediators is enhanced by the sensitisation of mast cells by DNP-specific IgE and this is 
accompanied by the induction of a slight increase in expression of the IL-33 receptor, ST2 (Fig. 1a–d and results 
not shown). Supporting the role of IgE-mediated upregulation of ST2 in the enhancement of IL-33 functional 
responses, the release of lL-6 and IL-13 by PDMCs and BMMCs in response to stimulation with IL-33 + IgE is 
completely dependent on ST2-expression (Fig. 1e–h). Moreover, whilst IgE sensitisation of mast cells is associated 
with increased IL-33-mediated activation of ERK and NF-κB activation (the latter assessed in terms of degrada-
tion of the inhibitory element IκB), such IL-33 signalling was essentially abrogated in ST2-deficient PDMC and 
BMMC populations (Fig. 2a,b and results not shown). Enhancement of these key IL-33/ST2 signals1 therefore 
provides a molecular rationale for the increased mast cell responses to IL-33 observed following sensitisation 
with IgE.
By contrast, despite undergoing degranulation in response to antigen (DNP-HSA)-induced crosslinking of 
FcεRI (XL) or stimulation with PMA plus ionomycin (PMA/Iono), neither mast cell subtype degranulates in 
response to IL-33, either in the presence or absence of IgE sensitisation (Fig. 3a–d). As strong mobilisation of 
intracellular and extracellular calcium is key to FcεRI-mediated mast cell degranulation25,26, we therefore investi-
gated whether this reflected an inability of IL-33 to induce such signalling. Prior sensitisation by IgE was found to 
license ST2-dependent, IL-33 mobilisation of calcium (Fig. 3e–i): however, depletion of extracellular calcium by 
EGTA revealed that the low levels of calcium signalling observed, predominantly reflected influx of extracellular 
calcium with little or no release from intracellular stores (Fig. 3g,i), findings consistent with the failure of IL-33 
to cause degranulation.
Cross talk between ST2 and FcεRI signalling. Previous reports had suggested acute IL-33 and 
FcεRI signalling to be synergistic in promoting mast cell cytokine production27–30: perhaps reflecting this, 
FcεRI-mediated ERK activation and calcium mobilisation were found to be reduced in ST2-deficient PDMCs 
and BMMCs (Fig. 4a–f). However, and consistent with our data that IL-33/ST2 calcium signalling predominantly 
reflects influx (Fig. 3g,i), ST2-deficiency had no effect on the strong mobilisation of intracellular calcium stores 
(evident in the absence of extracellular calcium resulting from incubation with EGTA) observed following FcεRI 
crosslinking in PDMCs and only partially (~30%) inhibited this in BMMCs (Fig. 4d,f). Although, as shown in 
our previous studies13,14, we found crosslinking of FcεRI to induce variable levels of cytokine release by PDMCs 
(generally very low) and BMMCs, typically, FcεRI crosslinking resulted in little or no release of IL-6 or IL-13 
from either mast cell subtype derived from our WT and ST2−/− (BALB/c) littermate mice. Interestingly, therefore 
costimulation of such WT PDMCs or BMMCs via ST2 (with IL-33) and FcεRI resulted in a reduced production 
of IL-6 relative to that observed with IL-33 alone (Fig. 4g,h). By contrast, IL-13 release was not suppressed and 
indeed, such co-stimulation resulted in an ST2-dependent increase in production of IL-13 by PDMCs and whilst 
levels were generally not substantially altered, similarly, a significant increase was found in 1 of the 3 BMMC 
experiments performed (Fig. 4i,j and results not shown). Thus, these data perhaps suggest that cross talk between 
FcεRI and IL-33/ST2 may not simply enhance antigen-specific responses but rather, depending on the mast cell 
subtype and inflammatory context, modulate the phenotype of response generated.
Cross talk between ST2 and TLR4 signalling. ST2 has previously been reported to limit LPS/TLR4 
and BLP/TLR2 pro-inflammatory responses in monocytes21,22, putatively via sequestration of MyD8824. As we 
have previously demonstrated LPS also to mobilise calcium influx and induce cytokine responses in PDMCs 
and BMMCs13, we therefore investigated the effects of ST2 signalling on LPS/TLR4 responses in such mast cells 
(Fig. 5a–d). Using ST2-deficient cells, this revealed that ST2 similarly acted to limit LPS-induced IL-6 release from 
both PDMCs (1.40 ± 0.20 fold release in ST2−/− relative to WT cells, n = 3 experiments) and BMMCs (1.75 ± 0.22 
fold release in ST2−/− relative to WT cells, n = 3 experiments) as their secretion of this cytokine was substantially 
enhanced in its absence (Fig. 5a,c). By contrast, whilst ST2 deficiency strongly increased LPS-induced release 
of IL-13 from PDMCs (5.36 ± 0.52 fold release in ST2−/− cells, n = 3 experiments), it surprisingly abrogated all 
release of this cytokine by BMMCs (Fig. 5b,d). However, and reflecting the contradictory and divergent effects of 
ST2 signalling on LPS responses reported in studies exploiting IL-33, ST2-deficient cells, (decoy) fusion proteins 
and neutralising antibodies1,22,24,31,32, we find that IL-33 signalling significantly enhances LPS-induction of IL-6 
(PDMCs: 1.19 ± 0.06; BMMCs: 1.22 ± 0.14 fold release relative to LPS alone, n = 3 experiments) and particularly, 
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Figure 1. IL-33 stimulated cytokine production is ST2-dependent and enhanced by IgE-mediated sensitisation 
of PDMCs and BMMCs. PDMCs (a–f) and BMMCs (g,h) derived from WT or ST2−/− (BALB/c) mice were 
sensitized (a–h) or not (a–d) with murine anti-DNP IgE (0.5 μg/ml) overnight then stimulated with IL-33 (100 
ng/ml, (a–c); 10 ng/ml, e-h) for 24 h at 37 °C before release of IL-6, IL-13 or CCL2 was measured by ELISA. Data 
are presented as the mean values of triplicate samples ± SD and are from single experiments representative of 
2 (a–c) and 3 (e–h) independent experiments. Statistical analysis was performed using One-way ANOVA with 
Bonferroni’s multiple comparison test where *p < 0.05 and **p < 0.01. Flow cytometric analysis (d) of PDMCs 
sensitized (black line), or not (red line), with murine anti-DNP IgE overnight were gated for live 7AAD- cells 
and then analysed for ST2 expression against the relevant isotype control obtained with non-sensitised cells 
(grey plot).
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IL-13 (PDMCs: 3.60 ± 0.58; BMMCs: 2.24 ± 0.36 fold release relative to LPS alone, n = 3 experiments) in both 
mast cell subtypes (Fig. 5a–d). Moreover, this IL-13 enhancement is mediated via ST2 as it is lost in ST2-deficient 
mast cells with in some cases, IL-33 + LPS responses being less than those seen in response to (deregulated) LPS 
signalling alone: the slightly higher levels of IL-6 (but not IL-13) elicited by IL-33 + LPS in ST2−/− relative to WT 
mast cells presumably simply reflect the loss of the ST2-brake on LPS (alone) signalling.
To address the mechanisms underpinning the differential outcomes of IL-33/ST2-dependent modulation of 
LPS responses in PDMCs and BMMCs, we assessed the effects of LPS on ST2 and TLR4 expression in WT and 
ST2-deficient mast cells. This showed that LPS slightly upregulated expression of ST2, but not TLR4, and that 
TLR4 expression was not significantly modulated in ST2-deficient cells (Fig. 5e–j). Consistent with the enhance-
ment of cytokine responses observed, LPS-stimulated ERK activation was strongly enhanced in both PDMCs and 
BMMCs from ST2-deficient mice (Fig. 6a,b). Interestingly, therefore, whilst ST2-mediated deficiency or IL-33 
did not impact on LPS-mediated calcium mobilisation in PDMCs (Fig. 6c,d), such signalling was substantially 
reduced in ST2−/− BMMCs (Fig. 6e), demonstrating a rather unexpected dependence on ST2 expression for such 
signalling in this mucosal-like mast cell subtype.
ES-62 targets ST2-TLR4 crosstalk for mast cell immunomodulation. In direct contrast to the 
enhanced functional responses observed as a result of crosstalk between IL-33/ST2 and LPS/TLR4 signalling 
(Figs 5 and 6), but consistent with its ability to subvert TLR4 signalling to an anti-inflammatory phenotype, ES-62 
significantly reduces IL-33-induced IL-6, IL-13 and CCL2 production by PDMCs (Fig. 7a–c). This inhibition does 
not reflect modulation of ST2 expression13 but it is associated with reduced IL-33-mediated calcium mobilisation 
in these cells (Fig. 7d): these findings are reminiscent of our previous data demonstrating that whilst LPS/TLR4 
crosstalk with FcεRI results in increased calcium mobilisation and cytokine release, ES-62/TLR4 signalling inhib-
its FcεRI- and LPS-mediated calcium mobilisation and functional responses in mast cells10,13. As ST2 cross-talks 
with both FcεRI and TLR4, and indeed FcεRI and TLR4 show dependence on ST2 for calcium mobilisation, we 
therefore next investigated whether any inhibitory effects of ES-62 were impacted by ST2 expression.
ES-62 significantly reduced IL-33 + XL-stimulated IL-6 and IL-13 responses in WT mast cells: however, there 
were no significant differences between control and ES-62-treated PDMCs or BMMCs in ST2-deficient cells 
where the functional responses of ST2/FcεRI crosstalk were essentially abrogated (Fig. 7e–h). Likewise, the ES-62 
mediated suppression of LPS- and IL-33 + LPS-stimulated release of either IL-6 or IL-13 by PDMCs (Fig. 8a,b) 
was found to be lost in ST2-deficient cells. By contrast, the inhibition of LPS- and IL-33 + LPS-stimulation 
of IL-6 production remained intact in ST2−/− BMMCs and likewise, although responses were very low in 
the ST2-deficient cells, the LPS-induced release of IL-13 was inhibited by ES-62 in WT and ST2−/− BMMCs 
(Fig. 8c,d).
Discussion
The filarial nematode-derived immunomodulator, ES-62 protects against development of asthma in both acute 
and chronic mouse models11,12 at least in part by suppressing FεcRI- and LPS/TLR4-mediated activation of mast 
cells and downregulation of type-2 inflammatory responses10–14. IL-33/ST2 signalling has been proposed to 
fine-tune mast cell responses and indeed, FcεRI signalling has been reported to induce, in a calcium-dependent 
manner, IL-33 production by mast cells to amplify IgE-mediated inflammation33. Moreover, blockade of IL-33/
ST2 signalling was found to disrupt the late phase inflammatory response in a passive cutaneous anaphylaxis 
model of allergen-IgE-driven inflammation34. LPS has also been shown to augment FcεRI-driven mast cell resp
onses3–5,13,35,36 but in this case, it does not appear to involve the release of IL-33 from these cells34. Nevertheless, 
bacterial-induced tissue damage causes release of IL-33 and LPS signals, via TLR4, to elicit IL-33 production from 
monocytes and macrophages37,38, mucosal epithelial cells39 and DCs40,41. Thus, as both LPS/TLR4 and IL-33/ST2 
signal via MyD88, there is potential for crosstalk between TLR4 and IL-33R (ST2) on mast cells to promote patho-
genesis and exacerbation of asthma. Importantly, therefore given the protection afforded by ES-62 in acute and 
Figure 2. IL-33-stimulated ERK and NF-κB signalling is ST2-dependent and enhanced by IgE-mediated 
sensitisation of PDMCs and BMMCs. (a) PDMCs sensitized with murine anti-DNP IgE (0.5 μg/ml) overnight 
(IgE) or not (PBS) were cultured with IL-33 (10 ng/ml) for the indicated times and expression of activated 
(dually phosphorylated) and total ERK1 (p44) and ERK2 (p42) MAPK and IκBα analysed by Western blotting. 
β-actin was used as a loading control. (b) Wild type (WT) and ST2 −/− BMMCs sensitised with IgE were 
stimulated with IL-33 (10 ng/ml) for the indicated times and expression of activated (dually phosphorylated) 
and total ERK1 (p44) and ERK2 (p42) MAPK and IκBα analysed by Western blotting. β-actin was used as a 
loading control.
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Figure 3. The failure of IL-33 to induce mast cell degranulation is associated with lack of intracellular 
mobilisation of calcium. PDMCs (a,c) and BMMCs (b,d) were sensitized with murine anti-DNP IgE (0.5 μg/
ml) or not (a,b) and then stimulated with DNP-HSA (0.5 µg/ml) to induce cross-linking of FcεRI (XL), 
IL-33 (10 ng/ml) or PMA plus Ionomycin (both 1 μM) for 30 mins at 37 °C. Degranulation was determined 
as the % β-hexosaminidase released relative to the total activity of the cells and data are presented from a 
single experiment (a,b) or mean ± SEM values from the combined results of five (c) or three (d; IL-33, n = 2) 
independent experiments where statistical analysis was by one-way ANOVA with Bonferroni’s post test and 
*p < 0.05, **p < 0.01 and ***p < 0.001. WT or ST2 −/− PDMCs (e–g) and BMMCs (h,i) loaded with Fura-2/
AM and sensitised or not (e) with murine anti-DNP IgE (0.5 μg/ml) were stimulated at 50 s in serum-free HBSS 
with 100 ng/ml IL-33. Calcium mobilisation was recorded in real-time and for the analysis of intracellular 
mobilisation alone, the cells were stimulated in calcium-free buffer supplemented with 100 µM EGTA to remove 
all extracellular calcium (−Ca2+; g, i). Data are presented as the mean (baseline subtracted) values ± SEM from 
replicate biological analyses collated from at least two independent experiments as follows: for PDMCs, e: IL-33, 
n = 3, IL-33 + IgE, n = 4; f: WT n = 6, ST2−/− n = 5; g: IL-33 n = 7, IL-33-Ca2+ n = 7; for BMMCs, h: WT n = 6, 
ST2−/− n = 5; i: IL-33 n = 10, IL-33-Ca2+ n = 9. Statistical analysis was by two-way ANOVA where ***p < 0.001.
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Figure 4. FcεRI signalling and functional responses are modulated by ST2 expression. WT or ST2−/− PDMCs 
(a) or BMMCs (b) sensitized with murine anti-DNP IgE (0.5 μg/ml) overnight were cultured with DNP-HSA 
(0.5 μg/ml) to induce cross-linking (XL) of FcεRI for the indicated times and expression of pp44/pp42 dually 
phosphorylated and activated ERK1 and ERK2 relative to their total expression was analysed by Western 
blotting. WT or ST2−/− PDMCs (c,d) and BMMCs (e,f) sensitised with murine anti-DNP IgE (0.5 μg/ml) and 
loaded with Fura-2/AM were stimulated at 50 s in serum-free HBSS with DNP-HSA (0.5 μg/ml) to induce cross-
linking (XL) of FcεRI. Intracellular calcium mobilisation and influx were recorded in real-time, where for the 
analysis of intracellular mobilisation alone (d,f), the cells were stimulated in calcium-free buffer supplemented 
with 100 µM EGTA to remove all extracellular calcium. Data are presented as the mean (baseline subtracted) 
values ± SEM from replicate biological analyses from at least two independent experiments as follows: for 
PDMCs, (c and d) WT n = 6, ST2−/− n = 6; for BMMCs, (e) WT n = 7, ST2−/− n = 8; (f) WT n = 9, ST2−/− 
n = 10. Statistical analysis was by two-way ANOVA where ***p < 0.001. PDMCs (g,i) and BMMCs (h,j) derived 
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chronic models of asthma, our studies have identified that the differential cytokine responses in serosal (PDMC) 
and mucosal (BMMC) mast cell subsets shaped by complex interactions of ST2, FcεRI and LPS/TLR4 signals can 
be modulated by ES-62 via both ST2-dependent and independent mechanisms.
ES-62 acts to subvert inflammatory responses by normalising aberrant MyD88 signalling in a range of cell 
types (reviewed)16,42: thus reports that the augmentation of cytokine responses resulting from costimulation of 
BMMCs with IL-33 and allergen was abolished in MyD88 (C57BL/6)-deficient mice27, provides a rationale for 
the ability of the parasite product to target such FcεRI/ST2/TLR4 crosstalk in mast cells. Intriguingly there-
fore, given its ability to target ST2 and/or TLR4 responses in mast cells, ES-62 does not downregulate MyD88 
expression in PDMCs13: rather, as evidenced by the loss of its ability to modulate TLR4-associated responses in 
ST2−/− PDMCs, it appears to harness the negative regulatory properties of ST2 in sequestrating MyD88 to limit 
LPS/TLR4-driven (pathogenic) cytokine responses in macrophages24. By contrast, ES-62 can still dampen LPS or 
IL-33 + LPS functional responses in ST2−/− BMMCs, a finding reminiscent of its ability to inhibit TLR4-driven 
IL-12 production by monocytes from ST2-deficient mice43. These data indicate that ES-62 utilises distinct mecha-
nisms to inhibit LPS/TLR4-associated cytokine responses in PDMCs and BMMCs. Interestingly, therefore, whilst 
ES-62 downregulates expression of PKCα in both mast cell subtypes, it additionally downregulates MyD88 and 
TLR4/MyD88-associated PKCs, PKC-δ and PKC-ε in BMMCs but not PDMCs13,14. Collectively, therefore, these 
data suggest that whilst exploiting the ability of ST2 to sequester MyD88 is sufficient to enable ES-62 to uncouple 
TLR-mediated pro-inflammatory responses in PDMCs, direct degradation of MyD88 and associated transduc-
ers is required to reset homeostatic regulation in the context of the stronger TLR-biased cytokine responses of 
BMMCs.
Indeed, MyD88-integrated crosstalk between LPS/TLR4 and IL-33/ST2 appears to be complex, varying with 
respect to the mast cell subtype and particular response investigated. Also, the role of ST2 can differ depending 
on whether the effects of IL-33 stimulation or ST2-deficiency are examined (reviewed1), for example as exem-
plified by the divergent effects we have observed in the case of LPS-mediated stimulation of IL-13 responses in 
PDMCs and BMMCs. When the effects of IL-33 signalling and ST2-deficiency converge, this may reflect that 
IL-33 signalling can relieve ST2-sequestration of MyD88 and consequently promote TLR4 signalling and func-
tional responses. This idea may go some way to reconciling the apparently contradictory reports that whilst ST2 
KO studies indicate that (in the absence of IL-33) ST2 negatively regulates TLR4 signalling, IL-33 promotes it, the 
latter evidenced by findings that IL-33-deficient mice exhibit reduced responses to LPS1,44,45. That this is not the 
case for LPS-induced IL-13 responses in BMMCs suggests an unexpected requirement for ST2 in TLR4 signalling 
or alternatively that ST2 is required for downstream signalling driven by an autocrine factor released in response 
to LPS. Such a putative autocrine factor is unknown but does not appear to be IL-33 as although TLR-2 or −9 
signalling can induce IL-33 expression in BMMCs46, this is not the case for LPS/TLR432,37.
It is worth bearing in mind, however, that IL-33 can recruit additional receptors such as SIGIRR, which acts to 
negatively regulate TLR responses17 and has been shown to suppress the Type-2 inflammation-promoting actions 
of IL-33/ST2 signalling47, but can be downregulated by LPS in monocytes and neutrophils48. IL-33 has also been 
shown to induce formation of ST2, IL-1RAcP and c-Kit complexes and indeed, the presence of the c-kit ligand, 
stem cell factor is required for mast cell cytokine responses49. Likewise, the vesicular transport protein, TMED-1 
has been reported to be required for optimal IL-33 induction of cytokine production by HEK-293 cells and 
HUVECs50. Differential expression or recruitment of such regulatory elements may therefore be involved in shap-
ing the precise IL-33 functional responses delivered depending on the mast cell subset and inflammatory context.
In any case, MyD88 provides a potentially important point of convergence in driving type-2 cytokine produc-
tion in response to crosstalk amongst ST2, TLR4 and FcεRI receptors: this is because in addition to the widely 
established role of MyD88 in ST2 and TLR4 signalling, LPS has recently been shown to stimulate IL-13 release 
from mast cells via a MyD88-BLT2 signalling pathway that has previously been implicated in FcεRI signalling5. 
Indeed, whilst FcεRI crosslinking upregulates expression of BLT2, a LTB4 receptor on BMMCs, blockade with an 
antagonist or siRNA abolishes FcεRI production of type-2 cytokines19 and also the enhanced responses resulting 
from costimulation via LPS/TLR4 and FcεRI5. Moreover, antisense blockade of BLT2 strongly reduces airway 
inflammation and AHR in an OVA-induced IgE-dependent mouse model of asthma20 and a BLT2 antagonist 
suppresses the strongly enhanced levels IL-13 observed in this model following administration of LPS5. Thus, 
as ES-62 targets aberrant MyD88 signalling (reviewed15,16,42), this MyD88-BLT2 pathway potentially provides a 
unifying mechanism for its ability to suppress FcεRI and LPS/TLR4-stimulated cytokine responses in PDMCs 
and BMMCs13,14, as well as those modulated by IL-33/ST2, particularly as ES-62 does not modulate expression of 
either FcεRI or ST2 in PDMCs13.
The clinical relevance of our finding that ES-62 can target the ST2-FcεRI-TLR4 crosstalk driving allergic 
inflammation is not yet clear. However, we have previously shown ES-62 to be protective in mouse models of 
acute and chronic asthma and also contact hypersensitivity, and to induce hyporesponsiveness of mast cells 
in vivo, which persists even following ex vivo challenge with allergen or LPS10,12,51. Although, serosal (PDMC) 
and mucosal (BMMC)-like mast cells have been reported to differentially display strong degranulation versus 
cytokine/chemokine responses respectively, the precise roles of distinct mast cell phenotypes in pathogenesis, 
resolution of inflammation and tissue repair in allergy are not yet clear. This uncertainty reflects that mast cells 
from WT or ST2−/− mice were sensitized with murine anti-DNP IgE (0.5 μg/ml) overnight and stimulated with 
IL-33 (10 ng/ml) and/or DNP-HSA (0.5 µg/ml) for 24 h at 37 °C before release of IL-6 (g,h) and IL-13 (i,j) was 
measured by ELISA. Data are presented as the mean values of triplicate samples ± SD from single experiments 
representative of at least 2 independent experiments. Statistical analysis is by one-way ANOVA and Bonferroni’s 
post test where ***p < 0.001.
www.nature.com/scientificreports/
8Scientific RepoRts |  (2018) 8:4497  | DOI:10.1038/s41598-018-22716-9
Figure 5. PDMCs and BMMCs exhibit differential TLR4-ST2 cross-talk. PDMCs (a,b) and BMMCs (c,d) 
derived from WT or ST2−/− mice were sensitized with murine anti-DNP IgE (0.5 μg/ml) overnight and then 
stimulated with LPS (0.5 µg/ml) and/or IL-33 (10 ng/ml) for 24 h at 37 °C before release of IL-6 (a,c) and IL-13 
(b,d) was measured by ELISA. Data are presented as the mean values of triplicate samples ± SD from single 
experiments representative of three independent experiments. Statistical analysis is by one-way ANOVA 
and Bonferroni’s post test where *p < 0.05, **p < 0.001 and ***p < 0.001. Flow cytometric analysis (e–j) of 
WT and ST2−/− PDMCs (f,i) or BMMCs (e,g,h,j) sensitized with murine anti-DNP IgE and treated with LPS 
(0.5 μg/ml; WT, grey line; ST2−/−, pink line) or not (WT, black line; ST2−/−, red line) overnight. Live (7AAD−) 
CD117+FcεRI+ cells were analysed for ST2 (e–g) and TLR4 (h–j) expression relative to the relevant isotype 
controls (grey plots) in terms of the geometric mean fluorescence (GMFI). Data presented are the mean ± SEM 
values combined from at least three independent experiments and statistical analysis is by one-way ANOVA and 
Bonferroni’s post-test where **p < 0.01 and ***p < 0.001 relative to the “None” WT control.
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only fully mature functionally, and in a bespoke manner, in response to tissue-specific factors and the inflam-
matory context of their microenvironment, as evidenced by the ability of BMMCs to reconstitute both serosal 
and mucosal mast cells in vivo (reviewed52). Nevertheless, ES-62 appears able to reduce mast cell numbers and 
suppress their proinflammatory functions in bronchoalveolar lavage fluid (BALF; mucosal), airway epithelial 
lung tissue and skin (serosal/connective tissue) to reset immune homeostasis in models of allergic inflamma-
tion10,12,51 as well as differentially target both mature mast cells and their immature precursors in a mast cell 
subtype-, receptor and response-specific manner in vitro13. Collectively, these findings suggest that the parasite 
product is capable of distinct actions reflecting the plasticity of the mast cell population and site and inflamma-
tory context of the microenvironment in order to effect resolution of harmful inflammation and promote tissue 
repair whilst maintaining protective responses to fight infection. Consistent with this idea that ES-62 offers “safe” 
immunomodulation16,42, while it typically reduces degranulation and cytokine response of “healthy“ mast cells 
in vitro by some 20–30%, it exhibits more profound inhibition of mast cell responses under conditions of allergic 
inflammation10,12,51.
Reflecting potential differential effects, our preliminary data (Coltherd, Harnett & Harnett, unpublished) indi-
cate that the protection afforded against acute OVA/alum-induced AHR is associated with significant reduction 
in the levels of mast cell protease (MCPT)-1 in the BALF, that presumably reflects ES-62-mediated suppression 
of mast cell degranulation. By contrast, in the chronic OVA (non-alum) model of asthma, where mast cells play 
roles both in the early inflammatory phase (via degranulation) and also in the later airway remodelling phases of 
disease, whilst reduced levels of mast cells were found in the lungs of ES-62-treated mice12, this was not associated 
with a significant decrease in BALF levels of MCPT-1 in the chronic phase of disease. Likewise, and consistent 
with release of IL-33 being very rapid and transient in nature in models of asthma (reviewed53), we did not detect 
any differences in BALF levels of IL-33 amongst the experimental groups in either the acute or chronic models 
of asthma. However, we did find that the BALF levels of soluble ST2, a mediator which can inhibit LPS-induced 
shock in vivo54, were significantly reduced in OVA, but not OVA + ES-62 mice, relative to those in the healthy 
PBS-treated control mice in the chronic asthma model.
Thus, we addressed how ES-62 might impact on IL-33/ST2 signalling in asthma by investigating its effects in a 
chronic OVA/alum model of asthma in WT and ST2 KO BALB/c mice55: whilst the majority (4/6) of the WT mice 
with OVA-induced pathology died before the end of the protocol, all such mice (6/6) treated with ES-62 survived. 
Likewise, all of the ST2 KO mice, irregardless of whether they were in the OVA or OVA + ES-62 cohorts, survived. 
Such protection by ES-62 and/or ST2 deficiency was associated with reduced serum levels of OVA-specific IgE 
with no significant differences in OVA-specific IgE levels being detected amongst the OVA + ES-62 WT, OVA 
ST2 KO and OVA + ES-62 ST2 KO mice. Allergen-specific IgE is pathogenic in asthma, presumably by driv-
ing FcεRI-mediated degranulation and cytokine secretion, including autocrine release of IL-33 and downstream 
effector signalling: thus, collectively these data suggest that at least some of the in vivo protective effects of ES-62 
in chronic models of asthma reflect modulation of IL-33/ST2 signalling. Whilst IL-33 promotes FcεRI and TLR4 
cytokine responses, particularly at low levels of allergen, and has been shown at the single cell level to boost 
FcεRI-mediated degranulation and generate high responder mast cells (reviewed56), low sub-activating levels of 
IL-33 can induce ST2-dependent BMMC hyporesponsiveness to bacterial cell wall (TLR4-agonist) products but 
not allergens, in vitro31. Such IL-33-mediated hyporesponsiveness could provide a homeostatic mechanism to 
limit undue inflammation and tissue damage at sites of microbial invasion31. Thus, ES-62-mediated suppression 
of FcεRI-mediated release of IL-33 and/or consequent ST2-promotion of FcεRI and TLR4 responses may effec-
tively harness this homeostatic mechanism for maintaining mast cell unresponsiveness and preventing allergic 
inflammation.
Materials and Methods
Mice. ST2-deficient mice and their wild type (WT) littermates were bred in-house on the BALB/c background 
and maintained at the University of Glasgow as we described previously43. Additional BALB/c and C57BL/6 mice 
Figure 6. PDMCs and BMMCs exhibit differential ST2-dependence for calcium signalling. WT or ST2−/− 
PDMCs (a) or BMMCs (b) sensitized with murine anti-DNP IgE (0.5 μg/ml) overnight were cultured with LPS 
(0.5 μg/ml) for the indicated times and expression of pp44/pp42 dually phosphorylated and activated ERK1 
and ERK2 relative to their total expression was analysed by Western blotting. PDMCs (c,d) and BMMCs (e) 
sensitised with murine anti-DNP IgE (0.5 μg/ml) and loaded with Fura-2/AM were stimulated at 50 s in serum-
free HBSS with LPS (0.5 μg/ml) and/or IL-33 (10 ng/ml). Calcium mobilisation data are presented as the mean 
(baseline subtracted) values ± SEM from replicate biological analyses as follows: for PDMCs, (c) WT n = 6, 
ST2−/− n = 6; (d) LPS n = 3, IL-33 n = 3, LPS + IL-33 n = 3, for BMMCs, (e) WT n = 9, ST2−/− n = 9. Statistical 
analysis was by two-way ANOVA where ***p < 0.001.
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Figure 7. ES-62 modulates IL-33 responses. PDMCs were sensitized with murine anti-DNP IgE (0.5 μg/ml) 
in the presence or absence of ES-62 (2 µg/ml) overnight and then incubated in medium ± IL-33 (10 ng/ml) for 
24 h at 37 °C before release of IL-6, IL-13 and CCL2 was measured by ELISA (a–c). Data are mean ± SD values 
where ***p < 0.001 and are from single experiments, which for IL-6 and IL-13 were representative of four-six 
experiments. Analysis of the latter data shows that ES-62 significantly reduces IL-33-induced IL-6 and IL-13 
production by PDMCs to 66.03 ± 16.82 n = 5, p < 0.05 and 59.85 ± 14 n = 6, p < 0.01 of the control responses 
respectively and by BMMCs to 81.23 ± 5.72 n = 4, p < 0.05 and 75.75 ± 8.13 n = 5, p < 0.05 of the control 
responses respectively. PDMCs (d) were sensitised with murine anti-DNP IgE (0.5 μg/ml) in the presence or 
absence of ES-62 (2 µg/ml) and then loaded with Fura-2/AM and stimulated at 50 s in serum-free HBSS with 
IL-33 (10 ng/ml). Calcium mobilisation data are presented as the mean (baseline subtracted) values ± SEM 
where for IL-33, n = 3 and for IL-33 + ES-62, n = 4 replicate biological samples from a single experiment 
representative of at least three independent experiments. Statistical analysis was by two-way ANOVA where *** 
p < 0.001. WT and ST2−/− PDMCs (e,f) and BMMCs (g,h) were sensitized with murine anti-DNP IgE (0.5 μg/
ml) in the presence or absence of ES-62 (2 µg/ml) overnight and then incubated in medium ± 0.5 µg/ml DNP-
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were obtained from Harlan-Olac (now Envigo): we observed variability in the signalling and levels of cytokine 
production by mast cells derived from the different strains of mice and also between BALB/c mice obtained from 
commercial sources and those WT littermates bred in house13,14. All animals were specified pathogen-free and 
maintained under standard ad libitum conditions in accordance with Home Office, U.K. animal guidelines and 
with the approval of the Animal Welfare Ethical Review Board (AWERB) at the University of Glasgow and the 
Ethical Review Board of the University of Strathclyde,
Preparation of endotoxin-free ES-62. ES-62 was purified to homogeneity (as confirmed by SDS-PAGE) 
from conditioned medium of cultures of adult Acanthocheilonema viteae using endotoxin-free reagents and 
used at < 0.003 endotoxin units/ml as determined using a Limulus Amebocyte Lysate QCL-1000 kit (Lonza 
Biologics)57.
Peritoneal-derived mast cells (PDMCs) and bone marrow–derived mast cells (BMMCs). Mature 
serosal mast cells, as characterised by their size, morphology and expression of proteoglycans like heparin (as 
indicated by toluidine blue staining) and tryptase (by enzyme histochemistry [Z-Gly-Pro-Arg-MNA as substrate 
and Fast Garnet as chromogen]) were isolated from the peritoneal cavity (Supplementary Figure 1) and such pop-
ulations of PDMCs were enriched as described previously13,58,59. Briefly, non-adherent cells harvested from the 
peritoneal cavity were cultured at 0.3 × 106 cells/ml in complete RPMI medium (RPMI medium with 10% FBS, 
4 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 1 mM sodium pyruvate, 100 μM non-essential 
amino acids and 50 μM β-mercaptoethanol; Invitrogen Life Technologies) supplemented with 4% conditioned 
medium from the SCF-secreting CHO cell line, KLS-C13.
BMMCs were derived by culture (at 0.5 × 106 cells/ml) of single cell suspensions of BM cells from femurs 
and tibias in complete RPMI medium supplemented with conditioned medium from KLS-C (1%; SCF) and 
IL-3-producing TOP3 (3%; IL-3) cell lines. These conditions generate cells, which although phenotypically simi-
lar to immature mast cells are widely used as a model of mucosal mast cells13,58,59
PDMCs and BMMCs were cultured at 37 °C/5% CO2 in tissue culture-treated flasks (Greiner Bio-one) for 
at least 28 days, with adherent cells being discarded. A purity of > 95% mast cells was routinely obtained as 
evidenced by flow cytometric analysis of surface expression of CD117, FcεR1 and ST2 and histological analy-
sis of toluidine blue staining13. Briefly, following blocking of Fcγreceptors with anti-CD16/32 antibodies (clone 
2.4G2 hybridoma supernatant), cells were labelled with the relevant flurochrome-conjugated or biotinylated 
antibodies (antibodies specific for CD117 [#47–1171], FcεRI [#11–5898, 12–5898] and TLR4/MD2 [#12–9924, 
17–9924] were obtained from eBioscience; whilst that reactive against ST2, was obtained from MD Bioproducts 
[#101001 F]) and developed where appropriate with flurochrome-conjugated streptavidin. Dead cells were 
excluded from the analyses by use of the Live/Dead® Viability/Cytotoxicity Kit (Invitrogen) or staining with 
7-AAD (7-Amino Actinomycin D; eBioscience), the latter immediately prior to acquiring a minimum of 10,000 
data events (Becton Dickinson LSR II or FACSCalibur™ flow cytometer), and expression levels subsequently 
analysed using FlowJo software (Tree Star Inc). Gating strategies were as reported previously13.
Mast Cell Stimulation. Mast cells were sensitised with murine anti-DNP IgE (0.5 µg/ml; IgE) in the pres-
ence or absence of ES-62 (2 µg/ml) for 18 h prior to stimulation, unless otherwise specified. Cells were incubated 
(generally 106 cells/ml) with medium alone (as a negative control), IL-33 (10 ng/ml) and/or DNP-HSA (0.5 µg/
ml) to crosslink FcεR1 (XL), LPS to activate TLR4 (0.5 µg/ml; Salmonella minnesota) or phorbol myristate acetate 
plus ionomycin (both 1 µM; PMA + Iono) and supernatants assayed for cytokine release whilst the cell pellets 
prepared for Western Blot analysis were stored at −20 °C13. ELISAs for IL-6, IL-13 and CCL2 [MCP-1] (limits 
of detection 4 pg/ml, 4 pg/ml and 15 pg/ml respectively; eBioscience) were performed on triplicate samples and 
developed using TMB substrate and absorbances determined using a TECAN Sunrise Microplate reader13.
Calcium Mobilisation. As described previously13, cells were loaded with Fura-2/AM (5 µM; Invitrogen) 
in HBSS medium (145 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM CaCl2, 10 mM HEPES) and supplemented 
with 0.18% (w/v) D-glucose and 0.2% (w/v) BSA for 30 min at 37 °C in the dark. Calcium-free HBSS supple-
mented with 100 µM EGTA (ethylene glycol tetra-acetic acid) was used for measurement of intracellular cal-
cium mobilisation in the absence of extracellular calcium. Cells (106) were stimulated as indicated at t = 50 s and 
measurements acquired in a Hitachi F-700 fluorescence spectrophotometer for up to 180 s, with calcium levels 
detected every 500 ms using excitation-emission ratios of 340/380 nm. Following each experiment Rmax and 
Rmin values were determined by the addition of 1% Triton-X100 and subsequent addition of 20 mM EGTA pH 
7.4, respectively13.
Mast Cell Degranulation. Detection of β-hexosaminidase release is widely used as a surrogate for histamine 
degranulation. Mast cells (0.2 × 106) were suspended in 200 µL Tyrodes buffer supplemented with 1% FCS and 
stimulated as indicated for 30 min at 37 °C. Supernatants were assayed using a Tecan Sunrise microplate reader (at 
405 nm), for release of β-hexosaminidase (normalised to the total cellular β-hexosaminidase determined following 
HSA plus 10 ng/ml IL-33 (XL + IL-33) for 24 h at 37 °C before release of IL-6 (e,g) and IL-13 (f,h) was measured 
by ELISA. Data are mean ± SD values where ***p < 0.001. Analysis of 3 independent experiments showed that 
ES-62 reduced IL-33 + XL-stimulated IL-6 and IL-13 production by PDMCs to 79.27 ± 12.42 and 59.98 ± 10.07, 
p < 0.05 of the control responses respectively and by BMMCs to 65.11 ± 26.72 and 65.60 ± 20.43, p < 0.05 of the 
control responses in WT, but not ST2KO mast cells.
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cell lysis by addition of 1% Triton-X 100) by incubation with 1 mM p-nitrophenyl-N-acetyl-β-d-glucosamine 
in 0.05 M citrate buffer, pH 4.5, followed by quenching with 0.1 M sodium bicarbonate buffer as described 
previously13.
Western Blotting. Mast cells (2 × 106/ml) were lysed by the addition of 50 µL ice-cold, modified RIPA lysis 
buffer (50 mM Tris buffer, pH 7.4 containing 150 mM sodium chloride, 2% (v/v) NP40, 0.25% (w/v) sodium 
deoxycholate, 1 mM EGTA, 10 mM sodium orthovanadate, 0.5 mM phenylmethylsulfonylfluoride and chymosta-
tin, leupeptin, antipain and pepstatin A [all at 10 µg/ml]) and resulting cell lysates stored at −20 °C as described 
previously13.
Cell lysates (30–40 µg protein per lane; BCA protein assay, Thermo Pierce) were resolved using the XCell 
SureLock Mini-Cell kit with NuPAGE Novex high-performance pre-cast Bis-Tris gels and NuPAGE buffers and 
reagents (Invitrogen) followed by transfer to membranes and Western Blotting as described previously13. Briefly, 
following blocking for 1 h in TBS/Tween-20/5% non-fat milk, membranes were incubated overnight at 4 °C with 
the appropriate primary detection antibody in TBS/Tween-20 with either 5% non-fat milk or 5% BSA prior to 
exposure to the appropriate horseradish peroxidise (HRP)-conjugated secondary antibody for 2 h at room tem-
perature and visualisation using the ECL detection system and Kodak X-Ray film. The data presented in the main 
text figures are cropped blots but representative full-length images of the relevant antibody specificities are shown 
in Supplementary Figure 1.
Figure 8. ST2 deficiency impacts differentially on ES-62-mediated modulation of signalling in PDMCs 
and BMMCs. WT and ST2−/− PDMCs (a,b) and BMMCs (c,d) were sensitized with murine anti-DNP IgE 
(0.5 μg/ml) in the presence or absence of ES-62 (2 µg/ml) overnight and then incubated in medium ± IL-33 
(10 ng/ml) and/or LPS (0.5 µg/ml) for 24 h at 37 °C before release of IL-6 (a,c) and IL-13 (b,d) was measured 
by ELISA. Data are mean ± SD values from a single experiment representative of at least two independent 
experiments where ***p < 0.001. Statistical analysis where three independent experiments were performed 
showed that whilst treatment with ES-62 resulted in 39.5 ± 19.8% p < 0.05 of the LPS- and 78.8 ± 9.0% p < 0.05 
of IL33 + LPS-stimulated IL-13 production by WT PDMCs relative to the appropriate control responses, this 
inhibition was abolished (106 ± 10 and 106 ± 6% of the LPS and IL-33 + LPS control responses, respectively) in 
ST2KO PDMCs. By contrast, the LPS-induced release of IL-13 was inhibited by ES-62 in both WT and ST2−/− 
BMMCs (70.6 ± 6.7% WT and 63.5 ± 9.2% p < 0.05 control responses, respectively).
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Statistical Analysis. Statistical analysis was performed using Graphpad Prism (Graphpad Software Inc) 
using unpaired t-tests or Mann-Whitney analysis for non-parametric data, two-way ANOVA or one-way ANOVA 
with Bonferroni’s post-test where p is significant at *p < 0.05, **p < 0.01 or ***p < 0.001.
Data availability. No meta data sets were generated or analysed during the current study and so all data 
generated or analysed during this study are included in this article and associated Supplementary file.
ST2-deficient mice. The authors would also like to give special thanks to Dr Andrew McKenzie (Medical 
Research Council Laboratory of Molecular Biology, Cambridge) for originally providing the ST2 KO mice to the 
University of Glasgow and which we used and described previously43.
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